RegulatoryAug 13, 2026, 04:09 PM
DNA X Raises $2.5M, Believes It Meets Nasdaq Equity Rule
AI Summary
DNA X, Inc. announced the sale of 416,667 shares of Series B Preferred Stock, generating $2.5 million in cash proceeds. The company believes this transaction enables it to meet The Nasdaq Capital Market's $2.5 million stockholders' equity requirement for continued listing. DNA X is awaiting Nasdaq's formal determination of compliance and has provided a pro forma stockholders' equity balance of $5.84 million as of August 7, 2026, reflecting the completed transactions.
Key Highlights
- Sold 416,667 shares of Series B Preferred Stock for $2.5 million in cash proceeds.
- Believes it meets Nasdaq Capital Market's $2.5 million stockholders' equity requirement.
- Awaiting Nasdaq's formal determination regarding compliance with the Equity Rule.
- Projected pro forma stockholders' equity of $5.84 million as of August 7, 2026.
- Q1 2026 actual stockholders' equity was $(983) thousand.
- Q2 2026 estimated stockholders' equity was $(1,516) thousand.
Price Impact
More from SONM